A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network.

Klaus Mross,Christian Dittrich,W.E. Aulitzky,Dirk Strumberg,J. Schütte,R M Schmid,S. Hollerbach,M Merger,Gerd Munzert,F. Fleischer,M. E. Scheulen

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network.

2012

Klaus Mross
Christian Dittrich
W.E. Aulitzky
Dirk Strumberg
J. Schütte
R M Schmid
S. Hollerbach
M Merger
Gerd Munzert
F. Fleischer
M. E. Scheulen

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naive patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network

Keywords:

Medicine
Drug
Proto-Oncogene Proteins
Pathology
Immunology
Polo-like kinase
Kinase
Cell Cycle Protein
Protein-Serine-Threonine Kinases
Adenocarcinoma
Pancreas
follow up studies
disease free survival
therapy naive
anticancer drug

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations